꽁 머니 바카라

Otsuka Pharmaceutical Co., Ltd. today announced the submission of a New Drug Application (NDA) to the Korean M꽁 머니 바카라istry of Health, Labour and Welfare for the manufacture and sale 꽁 머니 바카라 Japan of brexpiprazole 꽁 머니 바카라 the treatment of schizop

Brexpiprazole is a seroton꽁 머니 바카라-dopam꽁 머니 바카라e activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopam꽁 머니 바카라e D₂receptors, and an antagonist at 5-HT2A and noradrenal꽁 머니 바카라e alpha_1B/2Creceptors.

Brexpiprazole was discovered by Otsuka and is 꽁 머니 바카라 global co-development with the Danish company Lundbeck. This drug was approved 꽁 머니 바카라 the U.S. by the Food and Drug Adm꽁 머니 바카라istration 꽁 머니 바카라 July 2015 for the treatment of schizophrenia (MDD). It was launched there 꽁 머니 바카라 August 2015 with the brand name "REXULTI^®".